We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Urinary KIM-1 Concentration Interpreted in Detecting AKI

By LabMedica International staff writers
Posted on 25 Mar 2019
Image: The Urisys 2400 urine analyzer (Photo courtesy of Roche Diagnostics).
Image: The Urisys 2400 urine analyzer (Photo courtesy of Roche Diagnostics).
Kidney injury molecule-1 (KIM-1) has been identified as a biomarker for the assessment of nephropathy in various chronic kidney diseases (CKD). Extensive KIM-1 expression occurs in proximal tubule cells in patients with confirmed acute tubular necrosis.

Urinary KIM-1 concentrations were also significantly correlated with the expression of tissue KIM-1 in systemic lupus erythematosus patients. Such findings increase the potential use of urinary KIM-1 in the diagnosis or prognosis of CKD, but also results in the difficulties in the interpretation of urinary KIM-1 when it is used in the early detection of acute kidney injury (AKI).

Scientists collaborating with those at Queen’s University (Kingston, ON, Canada) obtained 188 urine samples were obtained from adults with normal kidney filtration. Of which 83 of the 188 showed negative urine protein, erythrocytes and leucocytes were used as normal controls. The remaining 105 samples showed at least one abnormal result suggesting possible pre-existing nephropathy.

Routine urine analysis was performed on an Urysis 2400 analyzer of the hospital core laboratory, using a multi-parameter test cassette that measures pH, protein (albumin), glucose, ketones, bilirubin, urobilinogen, nitrite, erythrocyte, leukocyte esterase, and specific gravity. The urinary KIM-1 concentrations were measured in duplicate for each sample using the Quantikine enzyme-linked immunosorbent assay (ELISA) kit. The limit of detection was 0.009μg/L.

The investigators reported that the results showed significantly increased urinary KIM-1 concentration in protein positive (protein +, erythrocyte +/-, leucocyte+/-) samples compared to controls that were negative for protein, erythrocytes, and leucocytes. Urinary KIM-1 concentrations were significantly higher when proteinuria was at trace concentration (0.25g/L) and correlated with the severity of proteinuria. The creatinine normalized urinary KIM-1 was significantly higher when urine protein was 0.75g/L to 5g/L. The reference interval for urinary KIM-1 was 0 to 4.19 μg/L, and for creatinine normalized urinary KIM-1 0 to 0.58 μg/mmol.

The authors concluded that baseline urinary KIM-1 concentrations were increased when there was detectable urine protein and correlated with its severity. The urinary KIM-1 concentrations should be interpreted with consideration of urine protein levels in individual patients. The study was published on March 7, 2019, in the journal Practical Laboratory Medicine.

Related Links:
Queen’s University

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Gold Member
Hematology Analyzer
Medonic M32B

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more